Condition: TTP - Thrombotic Thrombocytopenic Purpura · Sponsor: Fondazione Luigi Villa
ItaliTTP is an observational, prospective, single-arm, national, multicenter, non-pharmacological cohort study aimed at better defining and understanding the natural history, disease severity, and clinical outcomes of patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP) in Italy. A minimum of 132 consecutive patients with acute iTTP (first event or relapse) will be enrolled for 3 years, with the possibility of extension, with a follow-up period of 3 years.
This description comes directly from the study's public registry record.
Sandra Maccarone · +39 02 551 0709 · contact@fondazioneluigivilla.org
Ilaria Mancini, MSc, PhD · +39 02 5503 5414 · ilaria.mancini@guest.unimi.it
Always discuss trial participation with your own doctor first.
| Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico | Milan, MI, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06376786